Telemetry Investments’s Aclaris Therapeutics ACRS Stock Holding History

Telemetry Investments’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,043	Closed	-$154K	–	178
2022 Q2	$154K	Sell	11,043 -7,968	-42%	-$112K	0.18%	111
2022 Q1	$328K	Sell	19,011 -10,989	-37%	-$150K	0.52%	68
2021 Q4	$436K	Sell	30,000 -1,500	-5%	-$22.7K	0.56%	59
2021 Q3	$567K	Sell	31,500 -2,518	-7%	-$40.4K	0.76%	43
2021 Q2	$597K	Buy	34,018 +24,018	+240%	+$546K	0.82%	47
2021 Q1	$252K	Sell	10,000 -36,800	-79%	-$720K	0.28%	105
2020 Q4	$303K	Sell	46,800 -220,666	-83%	-$931K	0.51%	63
2020 Q3	$687K	Sell	267,466 -206,449	-44%	-$462K	1.49%	30
2020 Q2	$768K	Sell	473,915 -27,085	-5%	-$36.3K	2.09%	17
2020 Q1	$521K	Buy	501,000 +60,000	+14%	+$81.7K	1.82%	26
2019 Q4	$833K	Buy	441,000 +226,407	+106%	+$375K	2.78%	12
2019 Q3	$232K	Buy	214,593 +25,063	+13%	+$35.6K	0.67%	39
2019 Q2	$415K	Buy	189,530 +40,526	+27%	+$221K	0.32%	51
2019 Q1	$893K	Buy	149,004 +50,504	+51%	+$335K	0.45%	32
2018 Q4	$728K	Buy	98,500 +56,500	+135%	+$582K	0.46%	58
2018 Q3	$610K	Buy	42,000 +6,000	+17%	+$103K	0.28%	58
2018 Q2	$719K	Sell	36,000 -20,000	-36%	-$370K	0.27%	49
2018 Q1	$981K	Buy	+56,000	New	+$1.19M	0.37%	51

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Telemetry Investments's ACRS Position: Q3 2022 in Review

Telemetry Investments sold out of Aclaris Therapeutics (ACRS) in Q3 2022, closing a stake of 11,043 shares — an estimated $154K sold.

Telemetry Investments first reported a position in ACRS in Q1 2018 and held it in 18 quarters. The position peaked at $981K in Q1 2018. 127 funds tracked by Wall St. Rank hold ACRS as of Q3 2022.

Telemetry Investments reported no remaining Aclaris Therapeutics position as of Q3 2022 after selling out during the quarter.
Telemetry Investments sold 11,043 Aclaris Therapeutics shares in Q3 2022, an estimated $154K.
Telemetry Investments first reported a position in Aclaris Therapeutics in Q1 2018 and held it in 18 quarters.
Telemetry Investments's Aclaris Therapeutics position peaked at $981K in Q1 2018.
127 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2022.

Based on Telemetry Investments's 13F filing for Q3 2022, filed 17 Nov 2022.